Outcomes in pediatric autoimmune hepatitis



Autoimmune hepatitis (AIH) is a common cause of acute and chronic hepatitis in childhood. Once the diagnosis is established, treatment with corticosteroid or corticosteroid and azathioprine is indicated. Most children with AIH respond to such therapy and experience remission from active disease. Eliminating drug therapy while maintaining remission is the ultimate goal of therapy. The optimal duration of therapy before drug elimination is unclear. Relapse rate is inversely related to therapy duration before drug withdrawal; thus, discontinuing immunosuppressive treatment is considered only after at least 1 to 2 years of complete remission. When applying a slow and systematic approach, many children with AIH can successfully be weaned off immunosuppression completely. Even patients presenting in acute liver failure may avoid liver transplantation with early medical therapy. In about 10% of patients, treatment fails, requiring alternative therapies and/or liver transplantation as liver disease progresses. Less than 10% of children with autoimmune hepatitis die during 10 years of follow-up.

References and Recommended Reading

  1. 1.
    Czaja AJ: Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008, 48:1540–1548.PubMedCrossRefGoogle Scholar
  2. 2.
    Czaja AJ: Autoimmune liver disease. Curr Opin Gastroenterol 2006, 22:234–240.PubMedCrossRefGoogle Scholar
  3. 3.
    Krawitt EL: Autoimmune hepatitis. N Engl J Med 2006, 354:54–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Mieli-Vergani G, Vergani D: Autoimmune paediatric liver disease. World J Gastroenterol 2008, 14:3360–3367.PubMedCrossRefGoogle Scholar
  5. 5.
    Mieli-Vergani G, Vergani D: Autoimmune hepatitis. In: Liver Disease in Children, edn 3. Edited by Suchy FJ, Sokol RJ, Balistreri WF. New York: Cambridge University Press; 2007:447–458.Google Scholar
  6. 6.
    Kelly DA, ed: Diseases of the Liver and Biliary System in Children, edn 3. Hoboken, NJ: Wiley-Blackwell; 2008.Google Scholar
  7. 7.
    Murray KF, Hadzic N, Wirth S, et al.: Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr 2008, 47:395–405.PubMedCrossRefGoogle Scholar
  8. 8.
    Greene MT, Melin-Aldana H, Whitington PF: Outcome of pediatric autoimmune hepatitis [abstract S2080(576)]. Presented at Digestive Disease Week. San Diego, CA; May 17–22, 2008.Google Scholar
  9. 9.
    Seo S, Toutounjian R, Conrad A, et al.: Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 2008, 23:1410–1414.PubMedCrossRefGoogle Scholar
  10. 10.
    Al-Chalabi T, Underhill JA, Portmann BC, et al.: Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008, 48:140–147.PubMedCrossRefGoogle Scholar
  11. 11.
    Kerkar N, Annunziato RA, Foley L, et al.: Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006, 43:629–634.PubMedGoogle Scholar
  12. 12.
    Czaja AJ: Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008, 6:379–388.PubMedCrossRefGoogle Scholar
  13. 13.
    Montano-Loza AJ, Carpenter HA, Czaja AJ: Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007, 102:1005–1012.PubMedCrossRefGoogle Scholar
  14. 14.
    Verma S: In type 1 autoimmune hepatitis (AIH), should remission be redefined as normalization of transaminases? J Hepatol 2006, 44:819–820; auhor reply 820–821.PubMedCrossRefGoogle Scholar
  15. 15.
    Alvarez F: Autoimmune hepatitis and primary sclerosing cholangitis. Clin Liver Dis 2006, 10:89–107, vi.PubMedCrossRefGoogle Scholar
  16. 16.
    Zandieh I, Krygier D, Wong V, et al.: The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008, 22:388–392.PubMedGoogle Scholar
  17. 17.
    Cuarterolo M, Ciocca M, Velasco CC, et al.: Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006, 43:635–639.PubMedCrossRefGoogle Scholar
  18. 18.
    Larsen FS, Vainer B, Eefsen M, et al.: Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007, 13:3232–3236.PubMedGoogle Scholar
  19. 19.
    Ichai P, Duclos-Vallee JC, Guettier C, et al.: Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007, 13:996–1003.PubMedCrossRefGoogle Scholar
  20. 20.
    Montano-Loza AJ, Carpenter HA, Czaja AJ: Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008, 103:1944–1951.PubMedCrossRefGoogle Scholar
  21. 21.
    Miyake Y, Iwasaki Y, Terada R, et al.: Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006, 24:1197–1205.PubMedCrossRefGoogle Scholar
  22. 22.
    Khalaf H, Mourad W, El-Sheikh Y, et al.: Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant Proc 2007, 39:1166–1170.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Division of Pediatric Gastroenterology, Hepatology and NutritionChildren’s Memorial HospitalChicagoUSA

Personalised recommendations